| Outcome Measures: |
Primary: Mean Change in Glycosylated Hemoglobin (A1C), A1C change from baseline to 24 weeks, 24 weeks|Baseline A1C, baseline A1C, Baseline|The Percentages of Patient Achieving an A1C <7%, The percentages of patient achieving an A1C \<7% at endpoint, 24 weeks | Secondary: Changes in Fasting Plasma Glucose, fasting serum sugar change from baseline to 24 weeks, 24 weeks|Changes in High Sensitive C-reactive Protein, fasting high sensitive serum C-reactive protein change from baseline to 24 weeks, 24 weeks|Changes in Homoeostasis Model Assessment of Insulin Resistance (HOMA-IR), HOMA-IR change from baseline to 24 weeks, 24 weeks|Body Weight Change, body weight change from baseline to 24 weeks, 24 weeks|Percentages of Patients With Total Adverse Events (AE), percentages of total adverse events, 24 weeks|Change in Fasting Total-cholesterol, Total-cholesterol change from baseline to 24 weeks, 24 weeks|Change in Fasting Low-density Lipoprotein Cholesterol (LDL-C), LDL-C change from baseline to 24 weeks, 24 weeks|Change in Fasting Triglycerides(TG), TG change from baseline to 24 weeks, 24 weeks|Change in Fasting High-density Lipoprotein Cholesterol(HDL-C), HDL-C change from baseline to 24 weeks, 24 weeks|Change in Fasting Plasma Alanine-aminotransferase (ALT), ALT change from baseline to 24 weeks, 24 weeks|Percentages of Patients With Mild to Moderate Hypoglycemia, Incidence of mild to moderate hypoglycemia after treatment, 24 weeks|Percentages of Patients With Edema, proportion of edema after treatment, 24 weeks|Percentages of Patients With Gastrointestinal Adverse Events, Proportion of Gastrointestinal adverse events after treatment, 24 weeks|Percentages of Patients With Nasopharyngitis, Proportion of Nasopharyngitis after treatment, 24 weeks|Percentages of Patients With Severe Hypoglycemia, Proportion of severe hypoglycemia after treatment, 24 weeks|Baseline Fasting Plasma Glucose, Baseline fasting plasma glucose, baseline|Baseline High Sensitive C-reactive Protein, Baseline high sensitive C-reactive Protein, baseline|Baseline Homoeostasis Model Assessment of Insulin Resistance (HOMA-IR), Baseline HOMA-IR, Baseline HOMA-IR|Baseline Alanine-aminotransferase (ALT), Baseline alanine-aminotransferase, Baseline|Baseline Body Weight, Baseline body weight, Baseline|Baseline Total Cholesterol, Baseline Total cholesterol, Baseline|Baseline Triglyceride (TG), Baseline TG, Baseline|Baseline Low-density Lipoprotein Cholesterol (LDL-C), Baseline LDL-C, Baseline|Baseline High-density Lipoprotein Cholesterol (HDL-C), Baseline HDL-C, Baseline
|
